Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439222 | 1.00 | GPR119 (0.45) | GPR119SETD7MAP4K4NR1H2NR1H3 | |
| SCHEMBL29160800 | 0.88 | GPR119 (0.43) | GPR119SETD7MAP4K4NR1H2NR1H3 | |
| SCHEMBL29160802 | 0.88 | GPR119 (0.43) | GPR119SETD7MAP4K4NR1H2NR1H3 | |
| SCHEMBL7053182 | 0.82 | HSD17B10 (0.44) | GPR119NR1H2NR1H3 | |
| SCHEMBL3556342 | 0.82 | HSD17B10 (0.44) | GPR119NR1H2NR1H3 | |
| SCHEMBL344752 | 0.78 | TSHR (0.56) | GPR119SETD7MAP4K4NR1H2 | |
| SCHEMBL527701 | 0.78 | TSHR (0.56) | GPR119SETD7MAP4K4NR1H2 | |
| SCHEMBL271429 | 0.78 | TSHR (0.56) | GPR119SETD7MAP4K4NR1H2 | |
| SCHEMBL10196598 | 0.78 | SETD7 (0.46) | GPR119SETD7MAP4K4NR1H2 | |
| SCHEMBL10196611 | 0.78 | SETD7 (0.46) | GPR119SETD7MAP4K4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970323-B1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9670221-B2 | Furopyridines as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | GPR119 1482/4885SETD7 2139/4885MAP4K4 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.